Analyst firms · Barclays · GOSS
Barclays GOSS price target and rating history
Gossamer Bio Inc. (GOSS) · Health Care
Barclays rates Gossamer Bio Inc. (GOSS) Equal Weight with a $0.30 price target, as of its latest action on Feb 24, 2026. It has published 3 rating actions on GOSS since December 2022, including 0 upgrades and 2 downgrades. Across 4 firms with a GOSS price target in the last 12 months, the median target is $1. Barclays's $0.30 is 70% below that.
- Current rating
- Equal Weight
- Price target
- $0.30
- Median target, all firms
- $1
- Actions on GOSS
- 3
Barclays price target on GOSS
Every Barclays rating on GOSS
- Feb 24, 2026
- Jan 28, 2026
- Dec 7, 2022
How other firms rate GOSS
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Chardan Capital Markets | Buy | $160 | Oct 13, 2026 |
| Leerink Partners | Outperform | $1 | Jul 28, 2026 |
| Cantor Fitzgerald | Neutral | Mar 23, 2026 | |
| Wedbush | Neutral | $1 | Feb 24, 2026 |
| Barclays | Equal Weight | $0.30 | Feb 24, 2026 |
Questions about Barclays and GOSS
- What is Barclays's price target for GOSS?
- Barclays's latest stated price target for Gossamer Bio Inc. (GOSS) is $0.30, from its action on Feb 24, 2026.
- What is Barclays's rating on GOSS?
- Barclays rates GOSS Equal Weight, a neutral rating, as of Feb 24, 2026.
- When did Barclays last change its view on GOSS?
- On Feb 24, 2026, Barclays downgrades to Equal Weight from Overweight, price target $0.30.
- How does Barclays's GOSS target compare with other analysts?
- Across 4 firms with a GOSS price target in the last 12 months, the median target is $1. Barclays's $0.30 is 70% below that.
More GOSS rating histories
All Barclays ratingsGOSS news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.